Active Recombinant Mouse Ccl22 Protein (68 aa)
|Product Overview :||Recombinant Mouse Ccl22 Protein without tag was expressed in E. coli.|
- Gene Information
- Related Products
|Description :||MDC is a CC chemokine that is produced in B cells, macrophages, monocyte-derived dendritic cells, activated NK cells and CD4 T cells. It signals through the CCR4 receptor. MDC chemoattracts monocytes, dendritic cells and NK cells and exerts HIV suppressive activity.|
|Source :||E. coli|
|Form :||Sterile Filtered White lyophilized (freeze-dried) powder.|
|Bio-activity :||Fully biologically active when compared to standard. Determined by its ability to chemoattract human activated lymphocytes using a concentration range of 10.0-100.0 ng/mL, corresponding to a Specific Activity of ＞1 × 10^4 IU/mg.|
|Molecular Mass :||7.8 kDa, a single, non-glycosylated polypeptide chain containing 68 amino acids.|
|Protein Length :||68|
|AA Sequence :||GPYGANVEDSICCQDYIRHPLPSRL VKEFFWTSKSCRKPGVVLITVKNRD ICADPRQVWVKKLLHKLS|
|Endotoxin :||Less than 1 EU/μg of rMuMDC/CCL22 as determined by LAL method.|
|Purity :||>97% by SDS-PAGE and HPLC analyses.|
|Storage :||This lyophilized preparation is stable for several weeks at 2-8 centigrade, but should be kept at -20 centigrade for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 centigrade. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 to -70 centigrade. Avoid repeated freeze/thaw cycles.|
|Storage Buffer :||Lyophilized from a 0.2 μm filtered concentrated solution in 20mM PB, pH 7.4, 150mM NaCl.|
|Reconstitution :||We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/ml. Stock solutions should be apportioned into working aliquots and stored at < -20C. Further dilutions should be made in appropriate buffered solutions.|
|Gene Name :||Ccl22 chemokine (C-C motif) ligand 22 [ Mus musculus ]|
|Official Symbol :||Ccl22|
|Synonyms :||CCL22; chemokine (C-C motif) ligand 22; C-C motif chemokine 22; CC chemokine ABCD-1; small-inducible cytokine A22; activated B and dendritic cell-derived; small inducible cytokine subfamily A22; dendritic cell and B cell derived chemokine; small inducible cytokine subfamily A, member 22; SMALL INDUCIBLE CYTOKINE A22 PRECURSOR (CC CHEMOKINE ABCD-1) (ACTIVATED B AND DENDRITIC CELL-DERIVED); MDC; DCBCK; ABCD-1; Scya22;|
|Gene ID :||20299|
|mRNA Refseq :||NM_009137|
|Protein Refseq :||NP_033163|
|UniProt ID :||O88430|
|◆ Recombinant Protein|
|CCL22-082C||Active Recombinant Human CCL22 Protein (68 aa)||+Inquiry|
|CCL22-0627H||Recombinant Human CCL22 Protein, GST-Tagged||+Inquiry|
|CCL22-311H||Recombinant Human CCL22 Protein, His-tagged||+Inquiry|
|CCL22-2884M||Recombinant Mouse CCL22 Protein||+Inquiry|
|CCL22-1108P||Recombinant Pig CCL22 Protein, His-tagged||+Inquiry|
|CCL22-7728HCL||Recombinant Human CCL22 293 Cell Lysate||+Inquiry|
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Q&As (6)Ask a question
The expression of CCL22 gene is regulated by a variety of signaling pathways, including inflammatory factor-mediated signaling pathways, cytokine-mediated signaling pathways, and transcription factors.
Studies have shown that by interfering with the interaction of the CCL22 protein and its receptor CCR4, tumor growth, improve inflammatory response, and regulate autoimmune diseases can be inhibited. These findings provide potential application value for the development of corresponding therapeutic strategies.
A number of inhibitors or antagonists that interact with CCL22 proteins have been developed that block the binding of CCL22 to its receptor CCR4, thereby interfering with its biological function.
The mechanism of action of CCL22 protein in specific diseases can be studied through cell culture experiments, animal models, clinical samples, and related biochemical techniques.
There are complex interactions between CCL22 proteins and other chemokines. They may influence the migration and localization of immune cells by competing for receptors, mutual regulation of expression, etc.
Some studies have shown that in tumor immunotherapy, inhibiting the expression of CCL22 or interfering with its interaction with CCR4 can enhance the effect of immunotherapy and improve the survival rate of patients.
Customer Reviews (0)Write a review
Ask a Question for All Ccl22 Products
Required fields are marked with *
My Review for All Ccl22 Products
Required fields are marked with *